Terms: = Colorectal cancer AND DEK, D6S231E, 7913, ENSG00000124795, P35659 AND Treatment
5 results:
1. IMMUNOEXPRESSION OF dek AND PHOSPHO-P38 PROTEINS IN RECTAL cancer BEFORE CHEMORADIATION THERAPY.
Tadokoro RB; Cardili L; Artigiani Neto R; Paiotti APR; Oshima CTF; Forones NM
Arq Gastroenterol; 2022; 59(3):414-420. PubMed ID: 36102441
[TBL] [Abstract] [Full Text] [Related]
2. Very Long-Term treatment with a
Mutoh M; Yoshimura K; Fujii G; Nakamura T; Takeshita T; Wakabayashi K; Sakai T; Ishikawa H
Nutrients; 2020 May; 12(6):. PubMed ID: 32485893
[TBL] [Abstract] [Full Text] [Related]
3. The potential predictive value of dek expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
[TBL] [Abstract] [Full Text] [Related]
4. Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by dek/IMP3.
You S; Guan Y; Li W
Mol Med Rep; 2018 Jan; 17(1):1065-1070. PubMed ID: 29115492
[TBL] [Abstract] [Full Text] [Related]
5. dek is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J; Rodriguez-Remirez M; Borrero-Palacios A; Moreno I; Cebrian A; Gomez del Pulgar T; del Puerto-Nevado L; Vega-Bravo R; Puime-Otin A; Perez N; Zazo S; Senin C; Fernandez-Aceñero MJ; Soengas MS; Rojo F; Garcia-Foncillas J
BMC Cancer; 2014 Dec; 14():965. PubMed ID: 25515240
[TBL] [Abstract] [Full Text] [Related]
